Information Provided By:
Fly News Breaks for February 3, 2020
Feb 3, 2020 | 08:54 EDT
As previously reported, Evercore ISI analyst Joshua Schimmer upgraded Bluebird Bio (BLUE) to Outperform from In Line with a price target of $100, up from $86, telling investors that the company's LentiGlobin sickle cell therapy and broader pipeline remain undervalued. He thinks that a filing for LentiGlobin in sickle cell later this year could serve as a key value driver, said Schimmer, who also downgraded peer Crispr Therapeutics (CRSP) to In Line from Outperform this morning.
News For BLUE From the Last 2 Days
There are no results for your query BLUE